BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

468 related articles for article (PubMed ID: 33239067)

  • 1. Total cardiovascular or fatal events in people with type 2 diabetes and cardiovascular risk factors treated with dulaglutide in the REWIND trail: a post hoc analysis.
    Dagenais GR; Rydén L; Leiter LA; Lakshmanan M; Dyal L; Probstfield JL; Atisso CM; Shaw JE; Conget I; Cushman WC; Lopez-Jaramillo P; Lanas F; Munoz EGC; Pirags V; Pogosova N; Basile J; Sheu WHH; Temelkova-Kurktschiev T; Raubenheimer PJ; Keltai M; Hall S; Pais P; Colhoun HM; Riddle MC; Gerstein HC
    Cardiovasc Diabetol; 2020 Nov; 19(1):199. PubMed ID: 33239067
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiovascular safety for once-weekly dulaglutide in type 2 diabetes: a pre-specified meta-analysis of prospectively adjudicated cardiovascular events.
    Ferdinand KC; Botros FT; Atisso CM; Sager PT
    Cardiovasc Diabetol; 2016 Feb; 15():38. PubMed ID: 26912057
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design and baseline characteristics of participants in the Researching cardiovascular Events with a Weekly INcretin in Diabetes (REWIND) trial on the cardiovascular effects of dulaglutide.
    Gerstein HC; Colhoun HM; Dagenais GR; Diaz R; Lakshmanan M; Pais P; Probstfield J; Riddle MC; Rydén L; Xavier D; Atisso CM; Avezum A; Basile J; Chung N; Conget I; Cushman WC; Franek E; Hancu N; Hanefeld M; Holt S; Jansky P; Keltai M; Lanas F; Leiter LA; Lopez-Jaramillo P; Cardona-Munoz EG; Pirags V; Pogosova N; Raubenheimer PJ; Shaw J; Sheu WH; Temelkova-Kurktschiev T;
    Diabetes Obes Metab; 2018 Jan; 20(1):42-49. PubMed ID: 28573765
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial.
    Gerstein HC; Colhoun HM; Dagenais GR; Diaz R; Lakshmanan M; Pais P; Probstfield J; Riesmeyer JS; Riddle MC; Rydén L; Xavier D; Atisso CM; Dyal L; Hall S; Rao-Melacini P; Wong G; Avezum A; Basile J; Chung N; Conget I; Cushman WC; Franek E; Hancu N; Hanefeld M; Holt S; Jansky P; Keltai M; Lanas F; Leiter LA; Lopez-Jaramillo P; Cardona Munoz EG; Pirags V; Pogosova N; Raubenheimer PJ; Shaw JE; Sheu WH; Temelkova-Kurktschiev T;
    Lancet; 2019 Jul; 394(10193):121-130. PubMed ID: 31189511
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exploring potential mediators of the cardiovascular benefit of dulaglutide in type 2 diabetes patients in REWIND.
    Konig M; Riddle MC; Colhoun HM; Branch KR; Atisso CM; Lakshmanan MC; Mody R; Raha S; Gerstein HC
    Cardiovasc Diabetol; 2021 Sep; 20(1):194. PubMed ID: 34563178
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of dulaglutide on stroke: an exploratory analysis of the REWIND trial.
    Gerstein HC; Hart R; Colhoun HM; Diaz R; Lakshmanan M; Botros FT; Probstfield J; Riddle MC; Rydén L; Atisso CM; Dyal L; Hall S; Avezum A; Basile J; Conget I; Cushman WC; Hancu N; Hanefeld M; Jansky P; Keltai M; Lanas F; Leiter LA; Lopez-Jaramillo P; Muñoz EGC; Pogosova N; Raubenheimer PJ; Shaw JE; Sheu WH; Temelkova-Kurktschiev T
    Lancet Diabetes Endocrinol; 2020 Feb; 8(2):106-114. PubMed ID: 31924562
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial.
    Gerstein HC; Colhoun HM; Dagenais GR; Diaz R; Lakshmanan M; Pais P; Probstfield J; Botros FT; Riddle MC; Rydén L; Xavier D; Atisso CM; Dyal L; Hall S; Rao-Melacini P; Wong G; Avezum A; Basile J; Chung N; Conget I; Cushman WC; Franek E; Hancu N; Hanefeld M; Holt S; Jansky P; Keltai M; Lanas F; Leiter LA; Lopez-Jaramillo P; Cardona Munoz EG; Pirags V; Pogosova N; Raubenheimer PJ; Shaw JE; Sheu WH; Temelkova-Kurktschiev T;
    Lancet; 2019 Jul; 394(10193):131-138. PubMed ID: 31189509
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of dulaglutide on cognitive impairment in type 2 diabetes: an exploratory analysis of the REWIND trial.
    Cukierman-Yaffe T; Gerstein HC; Colhoun HM; Diaz R; García-Pérez LE; Lakshmanan M; Bethel A; Xavier D; Probstfield J; Riddle MC; Rydén L; Atisso CM; Hall S; Rao-Melacini P; Basile J; Cushman WC; Franek E; Keltai M; Lanas F; Leiter LA; Lopez-Jaramillo P; Pirags V; Pogosova N; Raubenheimer PJ; Shaw JE; Sheu WH; Temelkova-Kurktschiev T
    Lancet Neurol; 2020 Jul; 19(7):582-590. PubMed ID: 32562683
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Erectile function in men with type 2 diabetes treated with dulaglutide: an exploratory analysis of the REWIND placebo-controlled randomised trial.
    Bajaj HS; Gerstein HC; Rao-Melacini P; Basile J; Colhoun H; Conget I; Cushman WC; Dagenais GR; Franek E; Hanefeld M; Keltai M; Lakshmanan M; Lanas F; Leiter LA; Lopez-Jaramillo P; Pirags V; Pogosova N; Probstfield J; Raubenheimer P; Ryden L; Shaw JE; Sheu WH; Xavier D
    Lancet Diabetes Endocrinol; 2021 Aug; 9(8):484-490. PubMed ID: 34153269
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and Safety of Dulaglutide in Older Patients: A post hoc Analysis of the REWIND trial.
    Riddle MC; Gerstein HC; Xavier D; Cushman WC; Leiter LA; Raubenheimer PJ; Atisso CM; Raha S; Varnado OJ; Konig M; Lakshmanan M; Franek E
    J Clin Endocrinol Metab; 2021 Apr; 106(5):1345-1351. PubMed ID: 33537745
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of dulaglutide on vascular health indexes in subjects with type 2 diabetes: a randomized trial.
    Tuttolomondo A; Cirrincione A; Casuccio A; Del Cuore A; Daidone M; Di Chiara T; Di Raimondo D; Corte VD; Maida C; Simonetta I; Scaglione S; Pinto A
    Cardiovasc Diabetol; 2021 Jan; 20(1):1. PubMed ID: 33397395
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Placebo-controlled, randomized trial of the addition of once-weekly glucagon-like peptide-1 receptor agonist dulaglutide to titrated daily insulin glargine in patients with type 2 diabetes (AWARD-9).
    Pozzilli P; Norwood P; Jódar E; Davies MJ; Ivanyi T; Jiang H; Woodward DB; Milicevic Z
    Diabetes Obes Metab; 2017 Jul; 19(7):1024-1031. PubMed ID: 28294499
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A 24-week study to evaluate the efficacy and safety of once-weekly dulaglutide added on to glimepiride in type 2 diabetes (AWARD-8).
    Dungan KM; Weitgasser R; Perez Manghi F; Pintilei E; Fahrbach JL; Jiang HH; Shell J; Robertson KE
    Diabetes Obes Metab; 2016 May; 18(5):475-82. PubMed ID: 26799540
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biomarker Changes Associated With Both Dulaglutide and Cardiovascular Events in the REWIND Randomized Controlled Trial: A Nested Case-Control Post Hoc Analysis.
    Gerstein HC; Lee SF; Paré G; Bethel MA; Colhoun HM; Hoover A; Lakshmanan M; Lin Y; Pirro V; Qian HR; Ruotolo G; Ryden L; Wilson JM; Duffin KL
    Diabetes Care; 2023 May; 46(5):1046-1051. PubMed ID: 36897834
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Similar cardiovascular outcomes in patients with diabetes and established or high risk for coronary vascular disease treated with dulaglutide with and without baseline metformin.
    Ferrannini G; Gerstein H; Colhoun HM; Dagenais GR; Diaz R; Dyal L; Lakshmanan M; Mellbin L; Probstfield J; Riddle MC; Shaw JE; Avezum A; Basile JN; Cushman WC; Jansky P; Keltai M; Lanas F; Leiter LA; Lopez-Jaramillo P; Pais P; Pīrāgs V; Pogosova N; Raubenheimer PJ; Sheu WH; Rydén L
    Eur Heart J; 2021 Jul; 42(26):2565-2573. PubMed ID: 33197271
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dulaglutide and cardiovascular and heart failure outcomes in patients with and without heart failure: a post-hoc analysis from the REWIND randomized trial.
    Branch KRH; Dagenais GR; Avezum A; Basile J; Conget I; Cushman WC; Jansky P; Lakshmanan M; Lanas F; Leiter LA; Pais P; Pogosova N; Raubenheimer PJ; Ryden L; Shaw JE; Sheu WHH; Temelkova-Kurktschiev T; Bethel MA; Gerstein HC; Chinthanie R; Probstfield JL
    Eur J Heart Fail; 2022 Oct; 24(10):1805-1812. PubMed ID: 36073143
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of the once-weekly glucagon-like peptide-1 receptor agonist dulaglutide on ambulatory blood pressure and heart rate in patients with type 2 diabetes mellitus.
    Ferdinand KC; White WB; Calhoun DA; Lonn EM; Sager PT; Brunelle R; Jiang HH; Threlkeld RJ; Robertson KE; Geiger MJ
    Hypertension; 2014 Oct; 64(4):731-7. PubMed ID: 24980665
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low incidence of anti-drug antibodies in patients with type 2 diabetes treated with once-weekly glucagon-like peptide-1 receptor agonist dulaglutide.
    Milicevic Z; Anglin G; Harper K; Konrad RJ; Skrivanek Z; Glaesner W; Karanikas CA; Mace K
    Diabetes Obes Metab; 2016 May; 18(5):533-6. PubMed ID: 26847401
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of Pancreas Safety in the Development Program of Once-Weekly GLP-1 Receptor Agonist Dulaglutide.
    Nauck MA; Frossard JL; Barkin JS; Anglin G; Hensley IE; Harper KD; Milicevic Z
    Diabetes Care; 2017 May; 40(5):647-654. PubMed ID: 28283565
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiovascular risk reduction with once-weekly semaglutide in subjects with type 2 diabetes: a post hoc analysis of gender, age, and baseline CV risk profile in the SUSTAIN 6 trial.
    Leiter LA; Bain SC; Hramiak I; Jódar E; Madsbad S; Gondolf T; Hansen T; Holst I; Lingvay I
    Cardiovasc Diabetol; 2019 Jun; 18(1):73. PubMed ID: 31167654
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.